Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

GIST pipeline

Response and survival, trial by trial.

Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.

18 arms have a reported figure in this set.

Avapritinib 2

Avapritinib

Avapritinib 300 mg

300 mg · ITT

3L or later GIST (n = 240)

Comparator: regorafenib 160 mg

median progression-free survival: 4.2 months, primary analysis

VOYAGER · NCT03465722

Avapritinib

Regorafenib 160 mg

160 mg · ITT

3L or later GIST (n = 236)

median progression-free survival: 5.6 months, primary analysis

VOYAGER · NCT03465722

Bezuclastinib + Sunitinib 2

Bezuclastinib + Sunitinib

Bezuclastinib 600 mg + sunitinib 37.5 mg

600 mg + 37.5 mg · ITT

GIST after imatinib (n = 204)

Comparator: sunitinib 37.5 mg

median progression-free survival (BICR): 16.5 months, data cutoff 09.30.2025

Peak · NCT05208047

Bezuclastinib + Sunitinib

Sunitinib 37.5 mg continuous

37.5 mg · ITT

GIST after imatinib (n = 209)

median progression-free survival (BICR): 9.2 months, data cutoff 09.30.2025

Peak · NCT05208047

Imatinib 2

NB003 2

NB003

NB003, 2L to 4L or later

not stated in source · Single arm

GIST 2L to 4L or later (n = 158)

median progression-free survival: 9.2 months, data as of March 2025

NB003 Phase 1 · NCT04936178

NB003

NB003, 3L subgroup

not stated in source · Single arm

GIST 3L (n not stated in source)

median progression-free survival: 13.7 months, data as of March 2025

NB003 Phase 1 · NCT04936178

Olverembatinib (HQP1351) 1

Olverembatinib (HQP1351)

Olverembatinib 30 to 50 mg every other day

30 to 50 mg · Single arm

SDH-deficient GIST (n = 26)

median progression-free survival: 25.7 months, cutoff 11.13.2025

HQP1351SJ0003 · NCT03594422

Regorafenib 2

Regorafenib

Regorafenib 160 mg, 3 weeks on 1 off

160 mg · ITT

GIST after imatinib and sunitinib

Comparator: placebo

median progression-free survival: 4.8 months, primary analysis

GRID · NCT01271712

Regorafenib

Placebo

placebo · ITT

GIST after imatinib and sunitinib

median progression-free survival: 0.9 months, primary analysis

GRID · NCT01271712

Ripretinib 4

Ripretinib

Ripretinib 150 mg

150 mg · ITT

GIST after imatinib, sunitinib and regorafenib

Comparator: placebo

median progression-free survival (BICR): 6.3 months, primary analysis

INVICTUS · NCT03353753

Ripretinib

Placebo

placebo · ITT

GIST after imatinib, sunitinib and regorafenib

median progression-free survival (BICR): 1 months, primary analysis

INVICTUS · NCT03353753

Ripretinib

Ripretinib 150 mg

150 mg · ITT

GIST after imatinib (ITT n = 226)

Comparator: sunitinib 50 mg 4/2

median progression-free survival (IRR), ITT: 8 months, primary analysis

median progression-free survival, KIT exon 11 ITT: 8.3 months, primary analysis

median PFS, exploratory ctDNA KIT exon 11 + 17/18 only: 14.2 months, exploratory, Exploratory ctDNA analysis (Heinrich, Nat Med 2024); nominal P

INTRIGUE · NCT03673501

Ripretinib

Sunitinib 50 mg 4/2

50 mg · ITT

GIST after imatinib (ITT n = 227)

median progression-free survival (IRR), ITT: 8.3 months, primary analysis

median progression-free survival, KIT exon 11 ITT: 7 months, primary analysis

median PFS, exploratory ctDNA KIT exon 11 + 17/18 only: 1.5 months, exploratory

median PFS, exploratory ctDNA KIT exon 11 + 13/14 (sunitinib vs ripretinib 4.0): 15 months, exploratory

INTRIGUE · NCT03673501

Sunitinib 2

Sunitinib

Sunitinib 50 mg, 4 weeks on 2 off

50 mg · ITT

GIST after imatinib progression or intolerance

Comparator: placebo

median time to tumor progression: 27.3 weeks, interim analysis

median progression-free survival: 24.1 weeks, interim analysis

Study 1 · NCT00075218

Sunitinib

Placebo

placebo · ITT

GIST after imatinib progression or intolerance

median time to tumor progression: 6.4 weeks, interim analysis

median progression-free survival: 6 weeks, interim analysis

Study 1 · NCT00075218

Velzatinib (IDRX-42, GSK6042981) 1

Velzatinib (IDRX-42, GSK6042981)

Velzatinib 300 mg tablet (or 400 mg capsule), 2L

300 mg · Single arm

2L advanced GIST (n = 46)

median progression-free survival: 13.7 months, median follow up 14.7 months; cutoff 12.15.2025

StrateGIST 1 · NCT05489237

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.